Navigation Links
Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
Date:5/22/2013

BUFFALO, N.Y., May 22, 2013 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Second Annual Marcum LLP Microcap Conference, May 30, in New York, NY.

Neil Lyons , CPA, Chief Financial Officer of Cleveland BioLabs, will present the Company's oncology and biodefense programs on May 30 at 1:30 p.m. Eastern Time.  A live and archived webcast of the Company's presentation will be available on the Investors page of the Cleveland BioLabs website at www.cbiolabs.com.

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.

Contact:
Rachel Levine , Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439
E: rlevine@cbiolabs.com


'/>"/>
SOURCE Marcum LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ganeden Biotech® Moves Its State-Of-The-Art Lab To Its World Headquarters In Cleveland
2. New England Biolabs Releases the NEBNext Microbiome DNA Enrichment Kit
3. New England Biolabs opens seventh subsidiary in Singapore
4. New England Biolabs New Website Adds Technical Information, Easy Ordering, and Better Search
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
7. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
8. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
9. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
10. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
11. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... Mass. (PRWEB) , ... January 06, 2020 , ... ... for a Digital World at The Fletcher School at Tufts University, is pleased ... Sloan Foundation. The grant will be administered by Tufts University, and will help ...
(Date:12/31/2019)... (PRWEB) , ... December 31, 2019 , ... ... in expanding its pharmaceutical product development lab in Maryland. Emphasis will ... increased size and expanded capabilities, Vici Health Sciences will be well positioned to ...
(Date:12/27/2019)... N.J. (PRWEB) , ... December 27, 2019 , ... ... custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and ... year under new management . Following acquisition by CLJ Holdings in February, ...
(Date:12/18/2019)... SCOTTSDALE, Ariz. (PRWEB) , ... December 17, 2019 ... ... it has received its 31st FDA clearance for reprocessing Electrophysiology (EP) devices since ... where closest competitors, Stryker Sustainability Solutions and SterilMed (a Johnson & Johnson company) ...
Breaking Biology Technology:
(Date:2/6/2020)... , ... February 06, 2020 ... ... research organization (CRO) specializing in complex interventional medical device and pharmaceutical trials, ... Regulatory Strategy. In this newly established role, Dorothy oversees the development and ...
(Date:2/5/2020)... ... 04, 2020 , ... Crystal Diagnostics (CDx) announced today that ... related to proprietary liquid crystal technology for rapid and accurate detection of foodborne ... on December 3, 2019. Together, these patents protect the company’s liquid crystal technology ...
(Date:2/1/2020)... ... February 01, 2020 , ... Liver cancer, called hepatocellular carcinoma (HCC), occurs ... from the disease. HCC is the 5th most common cancer and the 2nd leading ... it comes to incidence of HCC, while China has half of all patients suffering ...
Breaking Biology News(10 mins):